Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

1. Use of Low-Dose Aspirin and Mortality After Prostate Cancer Diagnosis: A Nationwide Cohort Study. (PubMed)

Use of Low-Dose Aspirin and Mortality After Prostate Cancer Diagnosis: A Nationwide Cohort Study. Background: Recent studies suggest that aspirin use may improve survival in patients with prostate cancer. Objective: To assess the association between postdiagnosis use of low-dose aspirin and prostate cancer mortality. Design: Nationwide cohort study. Setting: Denmark. Patients: Men with incident prostate adenocarcinoma between 2000 and 2011. Measurements: Nationwide registry data on tumor (...) characteristics, drug use, primary prostate cancer therapy, comorbidity, and socioeconomic parameters. Postdiagnosis use of low-dose aspirin (75 to 150 mg) was defined as 2 or more prescriptions filled within 1 year after prostate cancer diagnosis. Follow-up started 1 year after prostate cancer diagnosis. In secondary analyses, low-dose aspirin use was assessed within exposure periods of 5 or 7.5 years after prostate cancer diagnosis. Results: Of 29 136 patients (median age, 70 years), 7633 died of prostate

2019 Annals of Internal Medicine

2. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. (PubMed)

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. BACKGROUND: Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer. METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic, castration-resistant (...) prostate cancer and a prostate-specific antigen doubling time of 10 months or less. Patients were randomly assigned in a 2:1 ratio to receive darolutamide (600 mg [two 300-mg tablets] twice daily) or placebo while continuing androgen-deprivation therapy. The primary end point was metastasis-free survival, with the presence of metastasis determined by independent central review of radiographic imaging every 16 weeks. RESULTS: In total, 1509 patients underwent randomization (955 to the darolutamide group

2019 NEJM

3. Biodegradable Rectal Spacers for Prostate Cancer Radiotherapy

Biodegradable Rectal Spacers for Prostate Cancer Radiotherapy Recommendation Report 21-5 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Biodegradable Rectal Spacers for Prostate Cancer Radiotherapy P Chung, J Brown, D D‘Souza, W Koll, S Morgan and the biodegradable spacer insertion during radiotherapy for prostate cancer recommendation report group (SPACER RRG) Report Date: January 16, 2019 For information about this document, please contact Dr (...) Spacers for Prostate Cancer Radiotherapy. Toronto (ON): Cancer Care Ontario: 2019, January 16. Program in Evidence- based Care Recommendation Report No.: 21-5. Copyright This report is copyrighted by Cancer Care Ontario; the report and the illustrations herein may not be reproduced without the express written permission of Cancer Care Ontario. Cancer Care Ontario reserves the right at any time, and at its sole discretion, to change or revoke this authorization. Disclaimer Care has been taken

2019 Cancer Care Ontario

4. Axumin for functional imaging of prostate cancer recurrence

Axumin for functional imaging of prostate cancer recurrence Axumin for functional imaging of prostate cancer Axumin for functional imaging of prostate cancer recurrence recurrence Medtech innovation briefing Published: 8 February 2019 nice.org.uk/guidance/mib172 pathways Summary Summary The technology technology described in this briefing is Axumin, a radiopharmaceutical agent. It is intended for use in positron emission tomography (PET) to detect suspected prostate cancer recurrence in people (...) who have elevated prostate-specific antigen levels after primary curative treatment. It is currently the only licensed PET tracer indicated for use in recurrent prostate cancer. The inno innovativ vative aspects e aspects are that it is a prostate cancer-specific PET tracer with a novel mechanism of action based on amino acid transport. Its longer half-life and shorter uptake period may allow use in more people with suspected prostate cancer recurrence compared with other PET tracers. The intended

2019 National Institute for Health and Clinical Excellence - Advice

5. Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer

Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers - Health Technology Wales > Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers Topic Status (...) Complete Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer. Outcome of the appraisal The adoption of 68 Ga prostate-specific membrane antigen (PSMA) positron emission tomography (PET) for the diagnosis of recurrent prostate cancer is partially supported by the evidence. The use of 68 Ga PSMA PET provides a high degree of diagnostic accuracy on which to base management decisions as compared

2019 Health Technology Wales

6. Remote monitoring or self-management for surveillance or follow up of prostate cancer

Remote monitoring or self-management for surveillance or follow up of prostate cancer Remote monitoring of prostate cancer - Health Technology Wales > Remote monitoring of prostate cancer Remote monitoring of prostate cancer Topic Status Incomplete Remote monitoring or self-management for surveillance or follow up of prostate cancer. Summary Health Technology Wales researchers searched for evidence on different methods of prostate remote monitoring/self-management. Although a range of evidence

2019 Health Technology Wales

7. Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial

Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial 30591354 2018 12 28 1873-7560 2018 Dec 24 European urology Eur. Urol. Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial. S0302-2838(18)31020-0 10.1016/j.eururo (...) .2018.12.015 Abiraterone and enzalutamide are associated with side effects that may impair health-related quality of life (HRQoL). To assess patient-reported HRQoL, depression symptoms, and cognitive function for abiraterone versus enzalutamide. We randomized 202 patients in a phase II study of abiraterone versus enzalutamide for first-line treatment of metastatic castration-resistant prostate cancer (ClinicalTrials.gov: NCT02125357). Patients completed Functional Assessment of Cancer Therapy-Prostate

2019 EvidenceUpdates

8. Large ten-year trial on treatment of localised prostate cancer will aid management decisions

Large ten-year trial on treatment of localised prostate cancer will aid management decisions Signal - Large ten-year trial on treatment of localised prostate cancer will aid management decisions Dissemination Centre Discover Portal NIHR DC Discover Large ten-year trial on treatment of localised prostate cancer will aid management decisions Published on 15 September 2016 New, long-term research indicates that active monitoring, with prompt treatment if needed, may be a better option than radical (...) surgery or radiotherapy for many men who have prostate cancer if it’s confined to the prostate gland. In the ProtecT trial, after an average of ten years, few men died of prostate cancer and there was no difference in survival between men receiving active monitoring and those who had radical treatments (which caused unpleasant side effects). But active monitoring did increase the risk of cancer progressing or spreading to other parts of the body. Longer follow-up will help to fully understand

2019 NIHR Dissemination Centre

9. Bone-targeting drugs improve quality of life, but not survival in prostate cancer that has spread to bone

Bone-targeting drugs improve quality of life, but not survival in prostate cancer that has spread to bone Signal - Bone-targeting drugs improve quality of life, but not survival in prostate cancer that has spread to bone Dissemination Centre Discover Portal NIHR DC Discover Bone-targeting drugs improve quality of life, but not survival in prostate cancer that has spread to bone Published on 27 September 2016 The drug zoledronic acid delayed the onset of bone complications by two months in men (...) with prostate cancer that had spread to the bone. Though it did not increase overall survival, it improved quality of life by reducing important complications such as fractures and spinal cord compression. The radioactive drug strontium-89 was also tested and delayed the combined outcome of bone-related complications, pain or death by about one month. It also had no effect on overall survival or the number of bone complications. Both treatments were compared with chemotherapy alone. Current NICE guidance

2019 NIHR Dissemination Centre

10. MRI scan before biopsy could detect more prostate cancer

MRI scan before biopsy could detect more prostate cancer Signal - MRI scan before biopsy could detect more prostate cancer Dissemination Centre Discover Portal NIHR DC Discover MRI scan before biopsy could detect more prostate cancer Published on 7 March 2017 In men with a raised prostate specific antigen (PSA) blood test, which can be a sign of prostate cancer, MRI scanning before standard biopsy could allow more targeted biopsies and increase diagnosis of medium and high-risk prostate cancer (...) . In this NIHR-funded study, 576 men with suspected prostate cancer received a multi-parametric (MP)-MRI scan in addition to transrectal ultrasound-guided (TRUS) biopsy. They also had template mapping (TPM) biopsy of the entire prostate to reliably diagnose cancer. Neither MP-MRI scan nor TRUS-biopsy were entirely accurate. However, if MP-MRI is used as an initial test, followed by TRUS-biopsy targeted at areas identified on the scan, 18% more cancers could be detected than by TRUS biopsy alone. It may also

2019 NIHR Dissemination Centre

11. Men feel physically and psychologically ill-prepared for prostate cancer surgery

Men feel physically and psychologically ill-prepared for prostate cancer surgery Signal - Men feel physically and psychologically ill-prepared for prostate cancer surgery Dissemination Centre Discover Portal NIHR DC Discover Men feel physically and psychologically ill-prepared for prostate cancer surgery Published on 28 November 2017 Following prostate cancer surgery men often experience physical changes, such as urinary incontinence and erectile dysfunction, causing negative emotions (...) and distress. This review found that men felt poorly prepared – psychologically and physically – for the changes they might experience after surgery. Surgery was often described as "life-changing", and men described worrying about their future. NICE recommend that men and their partners/carers are fully informed about prostate cancer treatment options and their possible complications, and are supported in decision-making. This includes having access to psychosexual support at any time. This global review

2019 NIHR Dissemination Centre

12. Single routine offer of a blood test for prostate cancer did not save lives

Single routine offer of a blood test for prostate cancer did not save lives Single routine offer of a blood test for prostate cancer did not save lives Dissemination Centre Discover Portal NIHR DC Discover Single routine offer of a blood test for prostate cancer did not save lives Published on 12 June 2018 Offering all men aged 50 to 69 a single, screening prostate-specific antigen (PSA) blood test did not prevent deaths from prostate cancer. This large trial included 573 UK general practices (...) and over 400,000 men. It found that men who were invited to have a PSA test were 19% more likely to be diagnosed with prostate cancer, but no less likely to die from the condition, over an average 10 years of follow up. Forty per cent of men took up the offer. Controversy over PSA testing has persisted for many years. Two previous trials have had conflicting findings about whether repeated PSA testing reduces prostate cancer deaths. In addition, concerns about test accuracy, over-diagnosis and over

2019 NIHR Dissemination Centre

13. Factors in men’s choice of active surveillance for low-risk prostate cancer

Factors in men’s choice of active surveillance for low-risk prostate cancer Factors in men’s choice of active surveillance for low-risk prostate cancer Dissemination Centre Discover Portal NIHR DC Discover Factors in men’s choice of active surveillance for low-risk prostate cancer Published on 7 August 2018 doi: Many personal, organisational and national factors can help or hinder men from choosing active surveillance over radical treatment when they have low-risk prostate cancer. Men are more (...) likely to adhere to this plan of regular monitoring if they and their families are fully informed and understand that it includes the option of further treatment if necessary. The recent ProtecT trial demonstrated that there was no difference in 10-year survival rates between men with low risk localised prostate cancer who were allocated to active surveillance and those who chose radical treatment. This is important because radical treatment carries the risk of side effects, such as incontinence

2019 NIHR Dissemination Centre

14. Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review

Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review 30391078 2018 11 04 1873-7560 2018 Oct 31 European urology Eur. Urol. Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review. S0302-2838(18)30836-4 10.1016/j.eururo.2018.10.041 Identification of early nodal recurrence after primary prostate cancer (PCa) treatment by functional imaging may guide metastasis-directed therapy such as salvage lymph node dissection (SLND). The aim (...) the oncological impact of SLND on long-term endpoints. When imaging identifies exclusive nodal recurrent prostate cancer, surgery directed to the positive lesions is safe and can offer at least a temporary biochemical response. The oncological role assessed by strong clinical endpoints remains uncertain. Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved. Ploussard Guillaume G Department of Urology, Saint Jean Languedoc/La Croix du Sud Hospital, and Institut

2019 EvidenceUpdates

15. Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up

Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up 30420254 2018 11 13 1873-7560 2018 Nov 09 European urology Eur. Urol. Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up. S0302-2838(18)30851-0 10.1016/j.eururo.2018.10.053 We assessed the effect of screening in the European Randomized study of Screening for Prostate Cancer (ERSPC) Rotterdam pilot 1 study cohort with men randomized in 1991-1992. A total of 1134 men were randomized on a 1:1 (...) basis to a screening (S) and control (C) arm after prostate-specific antigen (PSA) testing (PSA ≥10.0ng/ml was excluded from randomization). Further PSA testing was offered to all men in the S-arm with 4-yr intervals starting at age 55yr and screened up to the age of 74yr. Overall, a PSA level of ≥3.0ng/ml triggered biopsy. At time of analysis, 63% of men had died. Overall relative risk of metastatic (M+) disease and prostate cancer (PCa) death was 0.46 (95% confidence interval [CI]: 0.19-1.11

2019 EvidenceUpdates

16. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. (PubMed)

Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. BACKGROUND: Radical prostatectomy reduces mortality among men with clinically detected localized prostate cancer, but evidence from randomized trials with long-term follow-up is sparse. METHODS: We randomly assigned 695 men with localized prostate cancer to watchful waiting or radical prostatectomy from October 1989 through February 1999 and collected follow-up data through 2017. Cumulative incidence and relative (...) risks with 95% confidence intervals for death from any cause, death from prostate cancer, and metastasis were estimated in intention-to-treat and per-protocol analyses, and numbers of years of life gained were estimated. We evaluated the prognostic value of histopathological measures with a Cox proportional-hazards model. RESULTS: By December 31, 2017, a total of 261 of the 347 men in the radical-prostatectomy group and 292 of the 348 men in the watchful-waiting group had died; 71 deaths

2018 NEJM

17. Padeliporfin for untreated localised prostate cancer

Padeliporfin for untreated localised prostate cancer P Padeliporfin for untreated localised adeliporfin for untreated localised prostate cancer prostate cancer T echnology appraisal guidance Published: 21 November 2018 nice.org.uk/guidance/ta546 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after (...) and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Padeliporfin for untreated localised prostate cancer (TA546) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 17Contents Contents 1 Recommendations 4 2 Information about padeliporfin 6 3 Committee discussion 7

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

18. Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer

Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer 30391079 2018 11 04 1873-7560 2018 Oct 31 European urology Eur. Urol. Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer. S0302-2838(18)30816-9 10.1016/j.eururo.2018.10.028 (...) Better prostate cancer risk stratification is necessary to inform medical management, especially for African American (AA) men, for whom outcomes are particularly uncertain. To evaluate the utility of both a cell cycle progression (CCP) score and a clinical cell-cycle risk (CCR) score to predict clinical outcomes in a large cohort of men with prostate cancer highly enriched in an AA patient population. Patients were diagnosed with clinically localized adenocarcinoma of the prostate and treated

Full Text available with Trip Pro

2018 EvidenceUpdates

19. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial

Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial 30316827 2018 12 03 1474-5488 19 11 2018 Nov The Lancet. Oncology Lancet Oncol. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. 1504-1515 S1470-2045(18)30528-X 10.1016/S1470-2045(18)30528-X The NRG/RTOG 9413 study (...) showed that whole pelvic radiotherapy (WPRT) plus neoadjuvant hormonal therapy (NHT) improved progression-free survival in patients with intermediate-risk or high-risk localised prostate cancer compared with prostate only radiotherapy (PORT) plus NHT, WPRT plus adjuvant hormonal therapy (AHT), and PORT plus AHT. We provide a long-term update after 10 years of follow-up of the primary endpoint (progression-free survival) and report on the late toxicities of treatment. The trial was designed as a 2 × 2

2018 EvidenceUpdates

20. Hypofractionated Radiation Therapy for Localized Prostate Cancer

Hypofractionated Radiation Therapy for Localized Prostate Cancer ');//--> ');//--> Search in: Menu COOKIES REQUIRED In order to access this website, please configure your browser to support cookies. ASCO Family of Sites Journals Publications Education Other Sites 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2018 American Society of Clinical Oncology |

2018 American Society of Clinical Oncology Guidelines